“we've highlighted that the collection of the next wave of indications would add approximately $2 billion to peak year sales for Rinvoq.”

In context

“ment is getting a little better over the last few months? Jeffrey Ryan Stewart: Yes. So thanks. Yes, it's Jeff. So the data was quite impressive that you've seen, the recovery of the hair growth quite striking relative to other JAK inhibitors that we've seen report out and gain approvals. So the way that we thought about Rinvoq and the new indications is really sort of the third wave of how we've developed the product. So we had the big rheumatology indications to start out with, and we built atopic dermatitis and the IBD indications. And now we have this next set of indications, GCA, lupus, et cetera, which are all overlapping with the derm and the rum categories where we have this exceptional strength right now. So as we build that out, it's going to be, we think, quite significant. And we've highlighted that the collection of the next wave of indications would add approximately $2 billion to peak year sales for Rinvoq. Now we're going to have to continue to study this because it's sort of late breaking and understand could we get more momentum coming out of the transformational quality of this data because in the research that we've had with patients with alopecia, clearly, any sort of hair recovery helps out their perception of their disease, their immune disease. But when you look at the potential to get those SALT scores at that level, could we really see more momentum than we've studied the market so far? We'll have to see. But net-net, to your point, it's a very significant strategy for us that will start to play out here towards the end of the decade, starting in '26, '27, '28, and we're really encouraged with the data. In terms of additional color on the aesthetic, we've seen things pretty stable”